Core Viewpoint - Immuron Limited has announced the completion of an interim analysis for a clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) in collaboration with the US Naval Medical Research Command (NMRC) [1][2] Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases [14] - The company has developed two commercially available oral immunotherapeutic products for gut-mediated diseases [1] Clinical Trial Details - The NMRC funded the clinical trial, which involved a hyperimmune bovine colostrum product developed by Immuron using a conjugated vaccine targeting Campylobacter and ETEC [3][4] - The trial enrolled 27 volunteers in a randomized, placebo-controlled study, demonstrating a 10.4% protective efficacy against moderate to severe campylobacteriosis compared to the placebo group [5] Future Plans - Immuron plans to hold an end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to initiate Phase 3 clinical trials of Travelan® in the second half of 2025 [2] - The company anticipates topline results from a clinical study of Travelan® involving 866 participants, with 85% recruitment completed and results expected in April 2025 [2] Product Information - Travelan® is an orally administered passive immunotherapy that reduces the likelihood of contracting traveler's diarrhea, caused by pathogenic bacteria [12] - The product is available in Australia as a listed medicine and in Canada as a licensed natural health product, while in the U.S., it is sold as a dietary supplement for digestive tract protection [12] Industry Context - Infectious diarrhea is a common illness among travelers and military personnel, with a high priority for preventative treatments due to increasing antibiotic resistance among enteric pathogens [10] - The NMRC is developing new vaccines targeting Campylobacter and ETEC, as well as other pathogens, in collaboration with Immuron [8]
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study